SCHEMBL3533770

SCHEMBL3533770

Cc1ccccc1-n1c(=O)cc(C2CC2)n1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.39
ALOX5 P09917 2/20 0.39
NAPRT Q6XQN6 1/20 0.38
MGLL Q99685 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
POLB P06746 1/20 0.35
ALDH1A1 P00352 4/20 0.34
HPGD P15428 1/20 0.34
LMNA P02545 2/20 0.33
GLA P06280 1/20 0.33
TSHR P16473 1/20 0.33
MCOLN3 Q8TDD5 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ELANE P08246 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3527309 0.88 NPSR1 (0.36) MAPTMEN1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL3535467 0.85 MEN1 (0.41) MAPTMEN1KMT2ANAPRTMGLL
SCHEMBL3532956 0.85 HSD11B1 (0.42) MAPTMEN1KMT2AALOX5NAPRT
SCHEMBL3537437 0.84 LMNA (0.40) MAPTMEN1KMT2AL3MBTL1ALOX5
SCHEMBL3527587 0.81 MGLL (0.42) MAPTMEN1KMT2AMGLLPOLB
SCHEMBL3529348 0.81 MAPT (0.42) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL3533292 0.80 HSD11B1 (0.46) MAPTMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL3535423 0.80 DRD2 (0.40) NAPRTSMN1; SMN2ALDH1A1LMNATSHR
SCHEMBL3531384 0.80 NAPRT (0.57) MAPTMEN1KMT2ANAPRTSMN1; SMN2
SCHEMBL3529498 0.79 DRD2 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652057-B2 Pyrazolones as 11b-HSD1 inhibitors for diabetes HOFFMAN-LA ROCHE INC. (US) 2010-01-26 US disclosed
EP-1924562-A2 PYRAZOLONE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-05-28 EP disclosed
WO-2007025880-A2 PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-03-08 WO disclosed
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes F. HOFFMANN-LA ROCHE AG (CH) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049574-A1 New pyrazolones as 11b-HSD1 inhibitors for diabetes HSD11B1, HSD17B1, HSD17B7 MAPT 3706/4885MEN1 1683/4885KMT2A 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.